Literature DB >> 3899916

Specific cell-mediated responses to bacterial antigens and clinical correlations in reactive arthritis, Reiter's syndrome and ankylosing spondylitis.

P Sheldon.   

Abstract

In 2 cases of ReA seen during the acute phase and shown serologically to be due to Y. enterocolitica 0:3, the LT test showed a marked response using as antigen a freeze dried preparation of the causative organism. The test result correlated with the activity of the disease when repeated during a flare in the 1st case, and during remission in both. Patients with ReA/RS in general showed a significantly higher response to the yersinia and klebsiella antigens tested when compared to AS, suggesting an overall difference in cell-mediated immunity to these enteric bacteria. AS cases reacted significantly less than controls to K. pneumoniae under suboptimal conditions. K. pneumoniae was shown to enhance the LT response to yersinia, possibly through an adjuvant effect. This was found with AS, ReA and in controls, though whether it is of relevance in the etiopathogenesis of AS or ReA/RS remains far from clear. Acute non-traumatic synovitis of the knee, occurring de novo, or in association with psoriasis, inflammatory bowel disease, or as part of RS, may be accompanied by evidence of heightened reactivity to streptococci both by blood and synovial fluid mononuclear cells. In 1 case with serological evidence of streptococcal infection and erythema nodosum, these changes were found to parallel disease activity. ReA can, it appears, follow recent streptococcal infection, and be associated with B27.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899916     DOI: 10.1111/j.1600-065x.1985.tb01135.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  10 in total

1.  Polyclonal B cell activation in ankylosing spondylitis.

Authors:  P Barbieri; I Olivieri; G Benedettini; P Marelli; M L Ciompi; G Pasero; M Campa
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

2.  Determination of oxygen radical production in spondyloarthropathies by whole blood chemiluminescence.

Authors:  M Ristola; M Leirisalo-Repo; H Repo
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

Review 3.  Polyclonal B-cell activation by bacteria that induce nonsuppurative sequelae.

Authors:  W L Gross
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

4.  Synovial fluid antigen-presenting cells unmask peripheral blood T cell responses to bacterial antigens in inflammatory arthritis.

Authors:  P F Life; N J Viner; P A Bacon; J S Gaston
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

5.  HLA-B27, molecular mimicry, and ankylosing spondylitis: popular misconceptions.

Authors:  A F Geczy; J K Prendergast; J S Sullivan; L I Upfold; L E McGuigan; H V Bashir; M Prendergast; J P Edmonds
Journal:  Ann Rheum Dis       Date:  1987-02       Impact factor: 19.103

6.  Differential induction of bone marrow macrophage proliferation by mycoplasmas involves granulocyte-macrophage colony-stimulating factor.

Authors:  P M Stuart; G H Cassell; J G Woodward
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

7.  Studies of humoral and cell-mediated immunity to peptides shared by HLA-27.1 and Klebsiella pneumoniae nitrogenase in ankylosing spondylitis.

Authors:  N Tsuchiya; G Husby; R C Williams
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

8.  Oxygen radical production and trapping in subjects with previous Yersinia infection.

Authors:  M Ristola; T Metsä-Ketelä; M Leirisalo-Repo; H Repo
Journal:  Inflammation       Date:  1992-06       Impact factor: 4.092

9.  Antibody-mediated modulation of arthritis induced by Chlamydia.

Authors:  R G Rank; K H Ramsey; A J Hough
Journal:  Am J Pathol       Date:  1988-08       Impact factor: 4.307

10.  Yersinia-induced uveitis in Ireland.

Authors:  D F Larkin; M T Cafferkey; P Eustace
Journal:  Br J Ophthalmol       Date:  1988-12       Impact factor: 4.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.